GL331, a topoisomerase II inhibitor, induces radiosensitization of human glioma cells

Anticancer Research

Volumn 26, Issue 3 A, 2006, Pages 2149-2156

  Chen, Yun ^a   Lin, Tzu Yu ^a   Chen, Jin Cherng ^b   Yang, Hung Zen ^c   Tseng, Sheng Hong ^d  

^a FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^b BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^c HUALIEN ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

GL331; Glioma; Radiosensitization; Topoisomerase II inhibitor

Indexed keywords

DNA TOPOISOMERASE INHIBITOR; GL331 ENZYME; UNCLASSIFIED DRUG;

ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL CYCLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL KILLING; CELLULAR DISTRIBUTION; CLONOGENIC ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; FLUORESCENCE ACTIVATED CELL SORTING; GLIOMA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RADIOSENSITIZATION; TRANSITIONAL CELL CARCINOMA;

CELL DEATH; CELL DIVISION; COMBINED MODALITY THERAPY; DNA TOPOISOMERASES, TYPE II; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; ETOPOSIDE; G2 PHASE; GLIOMA; HUMANS; RADIATION-SENSITIZING AGENTS;

EID: 33745591646     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Salcman M: Epidemiology and factors affecting survival. In: Malignant Cerebral Glioma. Apuzzo MLJ (ed.). American Association of Neurological Surgeons, Illinois, pp. 95-109, 1990.
2. Weller M, Winter S, Schmidt C, Esser P, Fontana A, Dichgans J and Groscurth P: Topoisomerase-I inhibitors for human malignant glioma: differential modulation of p53, p21, bax and bcl-2 expression and of CD95-mediated apoptosis by camptothecin and beta-lapachone. Int J Cancer 73: 707-714, 1997.
3. Burris HA, Rothenberg ML, Kuhn JG and von Hoff DD: Clinical trials with topoisomerase I inhibitors. Semin Oncol 19: 663-669, 1992.
4. Giocanti N, Hennequin C, Balosso J, Mahler M and Favaudon V: DNA repair and cell cycle interactions in radiation sensitization by the topoisomerase II poison etoposide. Cancer Res 53: 2105-2111, 1993.
5. Haddock MG, Ames MM and Bonner JA: Assessing the interaction of irradiation with etoposide or idarubicin. Mayo Clin Proc 70: 1053-1060, 1995.
6. Lee CC and Huang TS: A novel topoisomerase II poison GL331 preferentially induces DNA cleavage at (C/G)T sites and can cause telomere DNA damage. Pharmaceut Res 18: 846-851, 2001.
7. Beauchesne P, Soler C, Rusch P, Fotso M J, Duthel R, Schmitt T and Brunon J: Phase II study of a radiotherapy/etoposide combination for patients with newly malignant gliomas. Cancer Chemother Pharmacol 44: 210-216, 1999.
8. Huang TS, Lee CC, Chao Y, Shu CH, Chen LT, Chen LL, Chen MH, Yuan CC and Whang-Peng J: A novel podophyllotoxin-derived compound GL331 is more potent than its congener VP-16 in killing refractory cancer cells. Pharmaceut Res 16: 997-1002, 1999.
9. Chang H, Shyu KG, Lee CC, Tsai SC, Wang BW, Lee YH and Lin S: GL331 inhibits HIF-1 alpha expression in a lung cancer model. Biochem Biophys Res Commun 302: 95-100, 2003.
10. Huang TS, Lee CC, Chang AC, Lin S, Chao CC, Jou YS et al: Shortening of microsatellite deoxy(CA) repeats involved in GL331-induced sown-regulation of matrix metalloproteinase-9 gene expression. Biochem Biophys Res Commun 300: 901-907, 2003.
11. Huang TS, Shu CH, Shih YL, Huang HC, Su YC, Chao Y, Yang WK and Whang-Peng J: Protein tyrosine phosphatase activities are involved in apoptotic cancer cell death induced by GL331, a new homolog of etoposide. Cancer Lett 110: 77-85, 1996.
12. Huang TS, Shu CH, Yang WK and Whang-Peng J: Activation of CDC 25 phosphatase and CDC 2 kinase involved in GL331-induced apoptosis. Cancer Res 57: 2974-2978, 1997.
13. Huang TS, Shu CH, Lee CC, Chen LT and Whang-Peng J: In vitro evaluation of GL331's cancer cell killing and apoptosis-inducing activity in combination with other chemotherapeutic agents. Apoptosis 5: 79-85, 2000.
14. Liu JM, Chen LT, Chao Y, Li AF, Wu CW, Liu TS, Shiah HS, Chang JY, Chen JD, Wu HW, Lin WC, Lan C and Whang-Peng J: Phase II and pharmacokinetic study of GL331 in previously treated Chinese gastric cancer patients. Cancer Chemother Pharmacol 49: 425-428, 2002.
15. Whang-Peng J and Huang TS: New trials of GL331, a novel topoisomerase II inhibitor, in treatment of solid tumors. J Intern Med Taiwan 8: 6-11, 1997.
16. Taniguchi K, Wakabayashi T, Yoshida T, Mizuno M, Yoshikawa K, Kikuchi A, Nakashima N and Yoshida J: Immunohistochemical staining of DNA topoisomerase IIα in human gliomas. J Neurosurg 91: 477-482, 1999.
17. Chen Y, Su YH, Wang CH, Wu JM, Chen JC and Tseng SH: Induction of apoptosis and cell cycle arrest in glioma cells by GL331 (a topoisomerase II inhibitor). Anticancer Res 25: 4203-4208, 2005.
18. Bobola MS, Blank A, Berger MS and Silber JR: Contribution of O6-methylguanine-DNA methyltransferase to monofunctional alkylating agent resistance in human brain tumor-derived cell lines. Mol Carcinog 13: 70-80, 1995.
19. Tseng SH, Bobola MS, Berger MS and Silber JR: Characterization of paclitaxel (Taxol) sensitivity in human glioma- and medulloblastoma-derived cell lines. Neuro-Oncology 1: 101-108, 1999.
20. Steel GG and Peckham MJ: Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Rad Oncol Biol Phys 5: 85-91, 1979.
21. Minehan KJ and Bonner JA: The interaction of etoposide with radiation: variation in cytotoxicity with the sequence of the treatment. Life Sci 53: PL237-242, 1993.
22. Shigematsu N, Kawata T, Ihara N, Kawaguchi O, Kutsuki S, Ishibashi R, Kubo A and Ito H: Effect of combined treatment with radiation and low dose etoposide on cell survival. Anticancer Res 21: 325-328, 2001.
23. Xie X, Sasai K, Shibuya K, Tachiiri S, Nihei K, Ohnishi T et al: p53 status plays no role in radiosensitization effects of SN-38, a camptothecin derivative. Cancer Chemother Pharmacol 45: 362-368, 2000.
24. Chen AY, Okunieff P, Pommier Y and Mitchell JB: Mammalian DNA topoisomerase I mediates the enhancement of radiation cytotoxicity by camptothecin derivatives. Cancer Res 57: 1529-1536, 1997.